Denali Therapeutics gains FDA approval for AVLAYAH, advancing to commercial stage in rare disease treatment.

Denali Therapeutics has achieved FDA accelerated approval for AVLAYAH, a treatment for Hunter syndrome, marking its transition from a speculative platform to a commercial-stage rare disease company. The company's TransportVehicle technology enables delivery of biologics across the blood-brain barrier, offering a unique advantage in treating neurodegenerative and lysosomal storage diseases. With $1.17 billion in liquidity and a focused initial launch, Denali is positioned with a 2.8-year financial runway, reducing near-term capital risk. Despite a high valuation based on sales multiples, the validated platform and pipeline potential justify the premium as the company embarks on early-stage commercial growth.